EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri iD

Immunity, Inflammation and Disease · 2026

DOI: 10.1002/iid3.70437 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, 2026. Verfasst von Nima Javanmehr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Babol University of Medical Sciences, Babol, Iran. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Nanoparticles, Nanotechnology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has revolutionized oncology, its efficacy remains constrained by the immunosuppressive tumor microenvironment (TME), off‐target toxicity, and poor biodistribution of therapeutic agents.

Objective

This review elucidates how engineered nanoparticles (NPs) are redefining immune‐oncology by enabling the precise delivery of immunomodulators, antigens, and genetic payloads to target cells, while reprogramming the TME to convert “cold” tumors into immunogenic “hot” landscapes.

Methods

A literature search was conducted using PubMed, Scopus, and Google Scholar. The review was performed in a narrative and non‐systematic manner, focusing on studies addressing nanotechnology‐enhanced cancer immunotherapy.

Results

We dissect the physicochemical and functional versatility of NPs, emphasizing size‐, charge‐, and ligand‐dependent strategies to enhance lymph node targeting, APC activation, and sustained cargo release. Innovations in metallic, lipid‐based, and biomimetic NPs are highlighted, including gold and lipid‐based NPs for enhanced immune responses. Furthermore, we explore combinatorial approaches, such as NP‐mediated co‐delivery of checkpoint inhibitors and chemotherapeutics, which amplify cytotoxic T‐cell responses and mitigate systemic toxicity. Clinical advancements, including Nab‐Paclitaxel and mRNA‐loaded lipid NPs, underscore the translational potential of these platforms, with trials demonstrating improved survival and manageable adverse profiles.

Conclusion

However, challenges persist in optimizing targeting precision, scalability, and long‐term safety. Integrating breakthroughs in material science, immunology, and bioengineering, this review charts a roadmap for next‐generation nano‐immunotherapies, advocating patient‐specific designs and multimodal regimens. As the field strides toward clinical maturity, nanotechnology is poised to unlock the full potential of immunotherapy, paving the way for adaptive, immune‐guided, and potentially curative cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyNanoparticlesNanotechnologyNanomedicineHumansTumor MicroenvironmentAnimalsCancer Vaccines

Stichwörter der Autor:innen

cancer immunotherapycombination therapynanoparticlesnanotechnologytumor microenvironment

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
  • Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Shahid Rajaei Hospital, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.

ORCID-Profile: Hossein Teimouri

Zitieren

APA

Javanmehr, N., Ashtyani, A. M., Ghafelehbashi, R., Mousavi, F., & Teimouri, H. (2026). Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70437

Vancouver

Javanmehr N, Ashtyani AM, Ghafelehbashi R, Mousavi F, Teimouri H. Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer. Immunity, Inflammation and Disease. 2026. doi:10.1002/iid3.70437

BibTeX
@article{Javanmehr2026,
  author = {Javanmehr, Nima and Ashtyani, Asal Moazzami and Ghafelehbashi, Robabehbeygom and Mousavi, Fateme and Teimouri, Hossein},
  title = {Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  doi = {10.1002/iid3.70437}
}
Kostenlos starten →